The third edition of ImmunoSkin underscored Almirall’s commitment to advancing the scientific understanding of skin and its diseases, and to pioneering innovation in medical dermatology and ...
Dupixent significantly reduced itch and hive activity from baseline; 41% of patients achieved well-controlled disease statusConfirmatory data to support US regulatory resubmission by year-end; if ...
Sanofi to present dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria at ACAAI: Paris Saturday, October 26, 2024, 12:00 Hrs [IST] Positive data from the ...